Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review
Description
Daiichi Sankyo Co Ltd (4568) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Daiichi Sankyo Co Ltd (Daiichi Sankyo) is a healthcare company that focuses on the discovery, development, and delivery of innovative medical solutions. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
Daiichi Sankyo Co Ltd Key Recent Developments
Dec 08,2025: Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio With Latest Research Updates From Enhertu in Breast Cancer Trials at SABCS
Dec 03,2025: Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen
Nov 12,2025: General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC Platform
Oct 23,2025: New Research Team for Multispecific Biologics at BioMed X Institute in Collaboration with Daiichi Sankyo
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Daiichi Sankyo Co Ltd (Daiichi Sankyo) is a healthcare company that focuses on the discovery, development, and delivery of innovative medical solutions. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
Daiichi Sankyo Co Ltd Key Recent Developments
Dec 08,2025: Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio With Latest Research Updates From Enhertu in Breast Cancer Trials at SABCS
Dec 03,2025: Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen
Nov 12,2025: General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC Platform
Oct 23,2025: New Research Team for Multispecific Biologics at BioMed X Institute in Collaboration with Daiichi Sankyo
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
72 Pages
- Section 1 - About the Company
- Daiichi Sankyo Co Ltd - Key Facts
- Daiichi Sankyo Co Ltd - Key Employees
- Daiichi Sankyo Co Ltd - Key Employee Biographies
- Daiichi Sankyo Co Ltd - Major Products and Services
- Daiichi Sankyo Co Ltd - History
- Daiichi Sankyo Co Ltd - Company Statement
- Daiichi Sankyo Co Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Section 2 – Company Analysis
- Company Overview
- Daiichi Sankyo Co Ltd - Business Description
- Product Category: Healthcare (OTC) Products
- Overview
- Performance
- Product Category: Others
- Performance
- Product Category: Prescription Drugs
- Overview
- Performance
- Geographical Segment: Europe
- Performance
- Geographical Segment: Japan
- Performance
- Geographical Segment: Other Regions
- Performance
- Geographical Segment: United States
- Performance
- R&D Overview
- Daiichi Sankyo Co Ltd - Corporate Strategy
- Daiichi Sankyo Co Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Daiichi Sankyo Co Ltd - Strengths
- Daiichi Sankyo Co Ltd - Weaknesses
- Daiichi Sankyo Co Ltd - Opportunities
- Daiichi Sankyo Co Ltd - Threats
- Daiichi Sankyo Co Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Daiichi Sankyo Co Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Dec 08, 2025: Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio With Latest Research Updates From Enhertu in Breast Cancer Trials at SABCS
- Dec 03, 2025: Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen
- Nov 12, 2025: General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC Platform
- Oct 23, 2025: New Research Team for Multispecific Biologics at BioMed X Institute in Collaboration with Daiichi Sankyo
- Oct 13, 2025: Daiichi Sankyo Advances Cancer Treatment Standards With Breast Cancer Trials At ESMO
- Oct 02, 2025: Daiichi Sankyo Establishes Third Research Institute in San Diego
- Sep 10, 2025: Daiichi Sankyo : Personnel Changes
- Sep 04, 2025: Ibex Medical Analytics Announces IVDR Certification for HER2 Biomarker Scoring Solution in Breast Cancer
- Jul 10, 2025: Daiichi Sankyo Appoints Global Head Under Global Management Structure
- May 28, 2025: Notice regarding head office relocation :Daiichi Sankyo Co., Ltd
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Daiichi Sankyo Co Ltd, Key Facts
- Daiichi Sankyo Co Ltd, Key Employees
- Daiichi Sankyo Co Ltd, Key Employee Biographies
- Daiichi Sankyo Co Ltd, Major Products and Services
- Daiichi Sankyo Co Ltd, History
- Daiichi Sankyo Co Ltd, Subsidiaries
- Daiichi Sankyo Co Ltd, Joint Venture
- Daiichi Sankyo Co Ltd, Key Competitors
- Daiichi Sankyo Co Ltd, Ratios based on current share price
- Daiichi Sankyo Co Ltd, Annual Ratios
- Daiichi Sankyo Co Ltd, Annual Ratios (Cont...1)
- Daiichi Sankyo Co Ltd, Annual Ratios (Cont...2)
- Daiichi Sankyo Co Ltd, Interim Ratios
- Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Daiichi Sankyo Co Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Daiichi Sankyo Co Ltd, Performance Chart (2021 - 2025)
- Daiichi Sankyo Co Ltd, Ratio Charts
- Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
